Following on from this work, our group focused on how miR-26a and miR-30b are implicated in this response to trastuzumab by examining the differences in miRNA expression in trastuzumab-sensitive, acquired-resistance, or innate-resistance HER2+ breast cancer cell lines. The gene discussed is ERBB2; the disease is breast cancer.